{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.90","upperLimit":"23.7","value":"4.00"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"6.0","value":"3.90"},{"groupId":"OG002","lowerLimit":"4.0","upperLimit":"6.0","value":"4.0"},{"groupId":"OG003","lowerLimit":"2","upperLimit":"8","value":"2.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.00","upperLimit":"8.10","value":"4.00"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"8.0","value":"5.00"},{"groupId":"OG002","lowerLimit":"2.00","upperLimit":"6.00","value":"4.00"},{"groupId":"OG003","lowerLimit":"2","upperLimit":"6","value":"3.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants who had RET-fusion positive NSCLC received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons. This arm was specifically planned for reporting PK data.","id":"OG000","title":"RET- Fusion Positive NSCLC Participants"},{"description":"Participants who had RET-fusion positive NSCLC or TC, or RET-mutation positive MTC, each with different genetic mutations received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons. This arm was specifically planned for reporting PK data.","id":"OG001","title":"Tumor-agnostic Participants"},{"description":"Participants who had RET-altered (fusion or mutation) solid tumors previously treated with a selective RET TKI received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons. This arm was specifically planned for reporting PK data.","id":"OG002","title":"RET-altered Solid Tumors Participants"},{"description":"Participants who had RET-mutation positive solid tumors received Pralsetinib 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons. This arm was specifically planned for reporting PK data.","id":"OG003","title":"RET-mutation Positive Tumors Other Than MTC Participants"}],"paramType":"MEDIAN","populationDescription":"PK evaluable population included all participants who received at least one dose of pralsetinib and from whom at least one post dose PK sample was collected. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Predose on 0.5, 1, 2, 4, 6, 8 and 24 hours postdose on Days 1 and 15 of Cycle 1 (1 cycle = 28 days)","title":"Phase 2: Tmax","type":"SECONDARY","unitOfMeasure":"hours"}